2016 TOP STORIES: Lilly Alzheimer’s drug fails in high-stakes trial
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
Pharmaceutical
Articles
Lilly partners with AstraZeneca on another Alzheimer’s treatment
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
Pharma stocks slide after Trump’s vow to control drug costs
President-elect Donald Trump promised to drive down the cost of medicines, defying investors who saw a boon in his election last month and injecting himself again into a contentious economic debate.
Pharmaceutical firm plans $10.4M in new equipment, 60 jobs
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
At Eli Lilly, tears, heartbreak and renewed determination
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
Pharmacy grads still finding jobs, but it’s getting tougher
Pharmacy grads used to have their pick of six-figure jobs. But competition stiffened after dozens of new schools opened, sharply increasing the supply of newly minted pharmacists.
Lilly shares slip after Bernie Sanders criticizes insulin prices
Makers of insulin became the latest target for Sen. Bernie Sanders, who has been going after pharmaceutical companies one by one over the issue of high U.S. drug prices.
Drug firms fighting ‘tooth and nail’ against California ballot measure
Drugmakers including Eli Lilly and Co. are becoming increasingly vocal in fighting a California ballot proposition designed to bring down prices on prescription medicine.
Lilly cancer drug lands accelerated FDA approval
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
Wall Street analysts jumping on Lilly train
For more than two years, Eli Lilly and Co. has pushed the message that the worst days are over and a brighter future is just around the corner. Now, finally, Wall Street is starting to believe.
Americans getting fed up over high drug prices
A new poll shows that a growing number of people feel drug prices are unreasonable, and they favor a variety of government actions to keep prices down.
Confluence Pharmaceuticals lands $1.3M in venture capital
Indianapolis-based Elevate Ventures said it made the investment through the 21st Century Research & Technology Fund, which is reserved for Indiana companies.
Pills, pens bring hope for drug companies in diabetes crunch
Drugmakers facing a price war in the diabetes market, including Indianapolis-based Eli Lilly and Co., are betting on new technologies to withstand the competition.
Clinton’s drug proposals ‘very negative’ for industry, top CEO says
The head of Pfizer Inc., America’s biggest drugmaker, said Democratic presidential nominee Hillary Clinton’s proposals to contain the price of pharmaceuticals would be “very negative” for the industry and are a step toward single-payer health care.
Under fire, maker of EpiPen launching cheaper, generic version
Mylan will start selling a cheaper version of the emergency allergy treatment after absorbing waves of criticism over a growing list price that made it unaffordable for many patients.
Lilly drug for Alzheimer’s gets fast-tracked by FDA
Named AZD3293, the drug belongs to a novel class of drugs that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
Indiana continues to lead U.S. in pharmacy robberies
There were more pharmacy robberies in Indiana last year than California, which has a population about six times larger.
Incoming Lilly CEO pick to focus globally
Dave Ricks will begin guiding the company during a period of relative calm compared with the trying times John Lechleiter navigated during his eight years at the helm.
Lilly CEO Lechleiter to retire at end of year
John Lechleiter has been the company’s CEO since 2008. The announcement Wednesday morning of his retirement comes one day after the firm announced strong revenue and profit for its second quarter, indicating that Lechleiter’s initiatives have paid off.
Anthem, Express Scripts dispute comes down to pricing
The agreement by Indianapolis-based Anthem Inc. to sell its pharmacy-benefits arm to St. Louis-based Express Scripts for $4.7 billion has turned the companies at each other’s throats, culminating in a multibillion-dollar legal battle that began early this year.